Story
Orexo Reports Wider Q2 Loss as Revenue Misses Estimates
Summary
Swedish pharmaceutical firm Orexo AB posted a wider net loss for the second quarter after revenue fell short of analyst forecasts, driven by higher research and development spending.
Orexo AB reported a wider net loss for the second quarter, with revenue that missed consensus estimates. The Swedish specialty pharmaceutical company said earnings per share came in at -SEK 2.92, as it navigates a period of increased investment and strategic changes.
Key Financials
The company's performance was marked by a significant top-line miss. Key figures from the report include:
- Revenue: SEK 3.50 million, well below the consensus analyst estimate of SEK 5 million.
- EBIT: A loss of -SEK 103.30 million.
- EBITDA: A loss of -SEK 95.10 million.
Orexo attributed the negative results to a year-over-year decline in revenue and a rise in operating expenses. The company cited continued spending on research and development as well as organizational adjustments following the divestment of its Zubsolv asset in the United States.
Pipeline and Future Outlook
AdDespite the quarterly loss, Orexo highlighted progress in its development pipeline. The company noted growing external interest in its AmorphOX drug delivery platform and confirmed it is in multiple partnering discussions.
Looking ahead, Orexo plans to resubmit its New Drug Application (NDA) for Izipry in the third quarter of 2026, with potential FDA approval anticipated in the first quarter of 2027. Additionally, a pivotal trial for its OX640 candidate is scheduled to begin in the fourth quarter of 2026, with results expected in the first quarter of 2027.
Financing and Legal Challenges
Orexo also stated that it is evaluating opportunities for additional financing. The company said the funds would be used to support its growth initiatives and to resolve ongoing legal matters related to the U.S. Department of Justice. This introduces a key variable for investors monitoring the company's capital structure and legal risks.
Read next
More on Stocks
CIBC Offers Compelling Value Profile Among Major Canadian Banks
While TD Bank trades at the lowest price-to-earnings multiple, an analysis of yield and upside potential positions Canadian Imperial Bank of Commerce (CIBC) as a more balanced value investment among its peers.
Volvo Cars Appoints Klaus Zellmer as Next CEO to Succeed Hakan Samuelsson
Volvo Cars has named Klaus Zellmer as its next president and chief executive officer, replacing the departing Hakan Samuelsson. The transition comes as the automaker pursues an aggressive growth strategy amid market challenges.
Analyst 'Strong Buy' Ratings Signal Upside for TSX-Listed Miners
Several Canadian gold and copper miners, including Equinox Gold and Kinross Gold, are attracting strong buy ratings from analysts who project double-digit upside potential based on recent company-specific catalysts.
Saudi Tadawul All Share Index Slips to 1-Month Low on Broad Sector Declines
Saudi Arabia's benchmark stock index, the Tadawul All Share, closed down 0.26% on Sunday to reach its lowest point in a month, dragged lower by weakness in the insurance and energy sectors.